Pic: Getty Images
Health & Biotech
InteliCare forms a groundbreaking partnership with the prestigious Peter MacCallum Cancer Centre entering the remote patient monitoring sector within the healthcare industry.
Perth-based SaaS company InteliCare Holdings (ASX:ICR) has taken a significant step into the healthcare sector announcing a groundbreaking partnership with the world-renowned Peter MacCallum Cancer Centre.
Under the agreement, Peter Mac will spearhead a pioneering pilot study designed to assess the efficacy of InteliCare’s remote patient monitoring (RPM) solution when compared to the current standards of care in an acute hospital setting.
The research grant-funded pilot will span nine months and involve 40 patients participating in the feasibility assessment. The trial will utilise InteliCare’s software as a bespoke platform for analysis and alerts, combined with the use of a wireless, cuffless Biobeat device for measuring blood pressure supplied by InteliCare’s partner Matrix Medical Innovations. The selection of InteliCare and Matrix for this project came after a rigorous evaluation of the RPM market. The endorsement underscores the trust placed in these companies’ capabilities.
The study primarily focuses on validating the accuracy of the Biobeat device using InteliCare as the platform and interface to clinical staff in two distinct settings: during exercise testing (ET) and post-cancer surgery. The potential benefits of this technology in the perioperative period are substantial, offering early complication detection, timely patient alerts, improved outcomes, and reduced healthcare costs.
A key player in the aged and disability sectors, the strategic alliance heralds InteliCare’s foray into remote patient monitoring (RPM). Remote patient monitoring has become an increasingly vital segment in the healthcare realm, addressing the surging demand for hospital services, enhancing care outcomes, and optimising healthcare efficiency.
It is a pivotal area of healthcare technology poised for significant growth.
InteliCare CEO Daniel Pilbrow said the partnership provided a significant opportunity for the company with remote patient monitoring forecast to grow at a CAGR between 6.8% and 14.4% over the next 3-5 years.
“Remote patient monitoring is a growth segment for healthcare, pivotal in improving patient outcomes, addressing hospital demand, and enhancing efficiency,” he said.
“This pilot provides InteliCare with the opportunity to extend the role of its platform into the remote patient monitoring segment. We’re looking at a market valued at approximately $1.5 billion underpinned by investment and government policy.”
This article was developed in collaboration with InteliCare, a Stockhead advertiser at the time of publishing.
This article does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.
Health & Biotech
Health & Biotech
Health & Biotech
